Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
Background Tenofovir alafenamide (TAF) has good viral suppression efficacy and less adverse effect than tenofovir disoproxil fumarate (TDF). Real-world studies on the antiviral efficacy and safety of switching from TDF to TAF in patients with chronic hepatitis B (CHB) are limited. Methods This retro...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PeerJ Inc.
2021-11-01
|
| Series: | PeerJ |
| Subjects: | |
| Online Access: | https://peerj.com/articles/12527.pdf |
| _version_ | 1797420892630810624 |
|---|---|
| author | Pei-Yuan Su Wei-Wen Su Yu-Chun Hsu Siou-Ping Huang Hsu-Heng Yen |
| author_facet | Pei-Yuan Su Wei-Wen Su Yu-Chun Hsu Siou-Ping Huang Hsu-Heng Yen |
| author_sort | Pei-Yuan Su |
| collection | DOAJ |
| description | Background Tenofovir alafenamide (TAF) has good viral suppression efficacy and less adverse effect than tenofovir disoproxil fumarate (TDF). Real-world studies on the antiviral efficacy and safety of switching from TDF to TAF in patients with chronic hepatitis B (CHB) are limited. Methods This retrospective study included 167 nucleos(t)ide analogue (NA)-naive patients with CHB. All the patients received TDF at least 12 months before switching and TAF at least 12 months after switching at a single medical center. The Friedman test with Dunn–Bonferroni post hoc tests and repeated-measures analysis of variance was used to analyze the effect of complete viral suppression, alanine aminotransferase (ALT) level normalization, renal function changes, body weight, and body mass index in the periods before and after switching. Results The mean age and TDF treatment duration were 52 ± 11 years and 2.8 years (interquartile range, 1.51–5.15 years), respectively. The complete viral suppression rate was similar between the time of switching and 48 weeks after switching to TAF (77.8% vs 76%, P = 1.000). The percentage of alanine aminotransferase (ALT) normalization increased from 26.3% at TDF start to 81.4% (P < 0.001) at time of switching and 89.2% at 48 weeks after switching to TAF (P = 0.428). The median estimated glomerular filtration rate decreased from 100.09 mL/min/1.73 m² at TDF start to 91.97 mL/min/1.73 m² (P < 0.001) at the time of switching and stabilized at 48 weeks after switching to TAF (93.47 mL/min/1.73m², P = 1.000). The body weight decreased from 69.2 ± 12.2 kg at TDF start to 67.4 ± 12.1 kg (P < 0.001) at the time of switching to TAF and returned to 68.7 ± 12.7 kg (P < 0.001) 48 weeks thereafter. The body mass index (BMI) decreased from 25 ± 3.3 kg/m² at TDF start to 24.5 ± 3.3 kg/m² (P = 0.002) at the time of switching to TAF and returned to 25.1 ± 3.6 kg/m² (P < 0.001) 48 weeks thereafter. Conclusions Our study showed that switching to TAF from TDF had good antiviral effectiveness and stabilized renal function. The body weight and BMI decreased during TDF therapy and regained after switching to TAF. |
| first_indexed | 2024-03-09T07:09:13Z |
| format | Article |
| id | doaj.art-455a0350dec340fd9e5ad6662d46c136 |
| institution | Directory Open Access Journal |
| issn | 2167-8359 |
| language | English |
| last_indexed | 2024-03-09T07:09:13Z |
| publishDate | 2021-11-01 |
| publisher | PeerJ Inc. |
| record_format | Article |
| series | PeerJ |
| spelling | doaj.art-455a0350dec340fd9e5ad6662d46c1362023-12-03T09:18:03ZengPeerJ Inc.PeerJ2167-83592021-11-019e1252710.7717/peerj.12527Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective studyPei-Yuan Su0Wei-Wen Su1Yu-Chun Hsu2Siou-Ping Huang3Hsu-Heng Yen4Department of Gastroenterology, Changhua Christian Hospital, Changhua, TaiwanDepartment of Gastroenterology, Changhua Christian Hospital, Changhua, TaiwanDepartment of Gastroenterology, Changhua Christian Hospital, Changhua, TaiwanDepartment of Gastroenterology, Changhua Christian Hospital, Changhua, TaiwanDepartment of Gastroenterology, Changhua Christian Hospital, Changhua, TaiwanBackground Tenofovir alafenamide (TAF) has good viral suppression efficacy and less adverse effect than tenofovir disoproxil fumarate (TDF). Real-world studies on the antiviral efficacy and safety of switching from TDF to TAF in patients with chronic hepatitis B (CHB) are limited. Methods This retrospective study included 167 nucleos(t)ide analogue (NA)-naive patients with CHB. All the patients received TDF at least 12 months before switching and TAF at least 12 months after switching at a single medical center. The Friedman test with Dunn–Bonferroni post hoc tests and repeated-measures analysis of variance was used to analyze the effect of complete viral suppression, alanine aminotransferase (ALT) level normalization, renal function changes, body weight, and body mass index in the periods before and after switching. Results The mean age and TDF treatment duration were 52 ± 11 years and 2.8 years (interquartile range, 1.51–5.15 years), respectively. The complete viral suppression rate was similar between the time of switching and 48 weeks after switching to TAF (77.8% vs 76%, P = 1.000). The percentage of alanine aminotransferase (ALT) normalization increased from 26.3% at TDF start to 81.4% (P < 0.001) at time of switching and 89.2% at 48 weeks after switching to TAF (P = 0.428). The median estimated glomerular filtration rate decreased from 100.09 mL/min/1.73 m² at TDF start to 91.97 mL/min/1.73 m² (P < 0.001) at the time of switching and stabilized at 48 weeks after switching to TAF (93.47 mL/min/1.73m², P = 1.000). The body weight decreased from 69.2 ± 12.2 kg at TDF start to 67.4 ± 12.1 kg (P < 0.001) at the time of switching to TAF and returned to 68.7 ± 12.7 kg (P < 0.001) 48 weeks thereafter. The body mass index (BMI) decreased from 25 ± 3.3 kg/m² at TDF start to 24.5 ± 3.3 kg/m² (P = 0.002) at the time of switching to TAF and returned to 25.1 ± 3.6 kg/m² (P < 0.001) 48 weeks thereafter. Conclusions Our study showed that switching to TAF from TDF had good antiviral effectiveness and stabilized renal function. The body weight and BMI decreased during TDF therapy and regained after switching to TAF.https://peerj.com/articles/12527.pdfTenofovir Disoproxil FumarateTenofovir alafenamideChronic hepatitis BSwitch |
| spellingShingle | Pei-Yuan Su Wei-Wen Su Yu-Chun Hsu Siou-Ping Huang Hsu-Heng Yen Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study PeerJ Tenofovir Disoproxil Fumarate Tenofovir alafenamide Chronic hepatitis B Switch |
| title | Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study |
| title_full | Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study |
| title_fullStr | Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study |
| title_full_unstemmed | Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study |
| title_short | Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study |
| title_sort | real world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis b a retrospective study |
| topic | Tenofovir Disoproxil Fumarate Tenofovir alafenamide Chronic hepatitis B Switch |
| url | https://peerj.com/articles/12527.pdf |
| work_keys_str_mv | AT peiyuansu realworldexperienceofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideinpatientswithchronichepatitisbaretrospectivestudy AT weiwensu realworldexperienceofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideinpatientswithchronichepatitisbaretrospectivestudy AT yuchunhsu realworldexperienceofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideinpatientswithchronichepatitisbaretrospectivestudy AT sioupinghuang realworldexperienceofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideinpatientswithchronichepatitisbaretrospectivestudy AT hsuhengyen realworldexperienceofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideinpatientswithchronichepatitisbaretrospectivestudy |